Next-Generation Sequencing-Based Detection of Gene Mutations and Its Association With Clinicopathological Features in Gastric Cancer
Abstract
Objective
To analyze the gene mutation profile of Chinese patients with gastric cancer and to explore its correlations with clinicopathological characteristics and prognosis.
Methods
Fifty-five patients with gastric cancer were enrolled. Next-generation sequencing was performed to detect mutations in cancer-related genes, microsatellite instability, and tumor mutational burden. The associations of high-frequency mutated genes with clinicopathological features and progression-free survival (PFS) were analyzed. Key findings were validated and ethnic heterogeneity was assessed using The Cancer Genome Atlas stomach adenocarcinoma cohort (n = 436).
Results
Somatic mutations were identified in 85.45% (47/55) of patients. The most frequently mutated genes were TP53 (29.09%), ARID1A (16.36%), CDH1 (14.55%), LRP1B (14.55%), and PIK3CA (12.73%). TP53 mutations were associated with T4 stage (P = 0.028) and diffuse-type gastric cancer (P = 0.008). CDH1 mutations were enriched in signet-ring cell carcinoma (P = 0.012) and poorly differentiated tumors (P = 0.006). Pathogenic germline mutations were identified in 20% (11/55) of patients. Univariate survival analysis revealed that CDH1 mutation was an independent poor prognostic factor for PFS (hazard ratio = 3.110, 95% confidence interval: 3.370-20.000). Validation in The Cancer Genome Atlas cohort confirmed that the poor prognostic effect of CDH1 mutation was present only in the Asian subgroup (hazard ratio = 5.00, 95% confidence interval: 2.01-12.43), demonstrating significant ethnic heterogeneity.
Conclusion
Chinese patients with gastric cancer exhibit a distinct gene mutation profile, and key gene mutations are closely associated with tumor aggressiveness. This multi-cohort validation study indicates ethnic differences in the prognostic value of genes such as CDH1, highlighting the importance of precision molecular classification in the Chinese population.
Keywords: Stomach neoplasms, Next-generation sequencing, Gene mutation, Prognosis, Precision medicine
Full Text:
PDFReferences
International Agency for Research on Cancer ( IARC ). GLOBOCAN 2022: Global Cancer Statistics 2022. (2024-02-08)[2025-05-20]. https://gco.iarc.fr/.
HAN B, ZHENG R, ZENG H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent, 2024, 4(1): 47-53. doi: 10.1016/j.jncc. 2024.01.006.
CHEN Y, JIA K, XIE Y, et al. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis. J Hematol Oncol, 2025, 18(1): 42. doi: 10.1186/s13045-025-01698-y.
LIN Q Y, DAI W G, LI Y, et al. Interpretation of the key updates in the 2025 edition of the Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of gastric cancer. Journal of Digestive Oncology(Electronic Version), 2025, 17(3): 299-307. doi: 10. 3969/j.issn.1674-7402.2025.03.004.
JANJIGIAN Y Y, CECCHINI M, SHITARA K, et al. Genomic landscape of late-stage gastric cancer: analysis from KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 studies. JCO Precis Oncol, 2025, 9: e2400456. doi: 10.1200/PO-24-00456.
OOKI A, OSUMI H, YOSHINO K, et al. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair. Gastric Cancer, 2024, 27(5): 907-931. doi: 10.1007/s10120-024-01523-4.
RACA G, ASTBURY C, BEHLMANN A, et al. Points to consider in the detection of germline structural variants using next-generation sequencing: A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med, 2023, 25(2): 100316. doi: 10.1016/j.gim. 2022.09.017.
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature, 2020, 578(7793): 82-93. doi: 10. 1038/s41586-020-1969-6.
JIANG T, WANG P, HUANG X E. Research progress of liquid biopsy in the diagnosis and treatment of gastric cancer. J Med Res, 2022, 51(5): 22- 25. doi: 10.3760/cma.j.cn421213-20221017-00761.
MA S, ZHOU M, XU Y, et al. Clinical application and detection techniques of liquid biopsy in gastric cancer. Mol Cancer, 2023, 22(1): 7. doi: 10.1186/s12943-023-01715-z.
USUI Y, TANIYAMA Y, ENDO M, et al. Helicobacter pylori, homologous-recombination genes, and gastric cancer. N Engl J Med, 2023, 388(13): 1181-1190. doi: 10.1056/NEJMoa2211807.
Society of Tumor Biomarkers, China Anti-Cancer Association, Society of Tumor Biomarkers, Shanghai Anti-Cancer Association. Expert consensus on BRCA germline mutation screening in Chinese population (2024 version). China Oncology, 2024, 34(2): 220-238. doi: 10.19401/j.cnki. 1007-3639.2024.02.010.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 2014, 513(7517): 202-209. doi: 10.1038/nature13480.
AJANI J A, D'AMICO T A, BENTREM D J, et al. Gastric Cancer, Version 2. 2025, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2025, 23(5): 169-191. doi: 10.6004/jnccn.2025.0022.
TOTOKI Y, SAITO-ADACHI M, SHIRAISHI Y, et al. Multiancestry genomic and transcriptomic analysis of gastric cancer. Nat Genet, 2023, 55(4): 581-594. doi: 10.1038/s41588-023-01333-x.
BLAIR V R, MCLEOD M, CARNEIRO F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol, 2020, 21(8): e386-e397. doi: 10.1016/S1470-2045(20)30219-9.
WANG H, DING Y, CHEN Y, et al. A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics. Gastric Cancer, 2021, 24(6): 1227-1241. doi: 10.1007/s10120-021-01201-9.
RYAN C E, FASAYE G A, GALLANIS A F, et al. Germline CDH1 variants and lifetime cancer risk. JAMA, 2024, 332(9): 722-729. doi: 10. 1001/jama.2024.10852.
ZHANG C, ZHANG J, XU F P, et al. Genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma. J Thorac Oncol, 2019, 14(11): 1912-1923. doi: 10.1016/j. jtho.2019.07.031.
CORSO G, MAGNONI F, MASSARI G, et al. CDH1 germline mutations in healthy individuals from families with the hereditary diffuse gastric cancer syndrome. J Med Genet, 2022, 59(4): 313-317. doi: 10.1136/jmedgenet-2021-108226.
DECOURTYE-ESPIARD L, GUILFORD P. Hereditary diffuse gastric cancer. Gastroenterology, 2023, 164(5): 719-735. doi: 10.1053/j.gastro. 2023.01.038.
XU B, MAIMAITIJIANG A, NUERBIYAMU D, et al. The multifaceted role of p53 in cancer molecular biology: insights for precision diagnosis and therapeutic breakthroughs. Biomolecules, 2025, 15(8): 1088. doi: 10. 3390/biom15081088.
USON P L S Jr, RIEGERT-JOHNSON D, BOARDMAN L, et al. Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a multicenter prospective study. Clin Gastroenterol Hepatol, 2022, 20(3): e508-e528. doi: 10.1016/j.cgh.2021.04.013.
Refbacks
- There are currently no refbacks.
